Dr. Mason on the Role of Surgery in Stage III NSCLC

Video

David P. Mason, MD, chief of thoracic surgery and lung transplantation, Baylor Scott & White Healthcare System, chief of lung transplantation, Baylor University Medical Center, discusses the role of surgery in stage III non–small cell lung cancer.

David P. Mason, MD, chief of thoracic surgery and lung transplantation, Baylor Scott & White Healthcare System, chief of lung transplantation, Baylor University Medical Center, discusses the role of surgery in stage III non—small cell lung cancer (NSCLC).

A number of factors may prevent patients from seeing a surgeon, even though one-third to one-half of patients with lung cancer require a multimodality approach. For example, a lot of patients present with stage III disease in which the role of surgery is not as well defined as it is in earlier stages.

As far as the conversation between a surgeon and a patient, Mason says he first likes to get a sense of the patient’s overall fitness, motivation, and willingness to undergo an intensive procedure in addition to receiving other medical therapy such as chemoradiation. Additionally, patients have to understand the level of risk associated with surgery, Mason adds.

Related Videos
Jeremy M. Pantin, MD, clinical director, Adult Transplant and Cellular Therapy Program, TriStar Centennial Medical Center, bone marrow transplant physician, Sarah Cannon Research Institute
Maria Hafez, MD, assistant professor, breast and sarcoma medical oncologist, director, Clinical Breast Cancer Research, Sidney Kimmel Medical College, Thomas Jefferson University
Zeynep Eroglu, MD
Sundar Jagannath, MBBS, director, Center of Excellence for Multiple Myeloma, professor of medicine (hematology and medical oncology), The Tisch Cancer Institute, Mount Sinai
Akriti Jain, MD
Raj Singh, MD
Gottfried Konecny, MD
Karim Chamie, MD, associate professor, urology, the University of California, Los Angeles
Mike Lattanzi, MD, medical oncologist, Texas Oncology
Ramez N. Eskander, MD